Abstract
This chapter discusses some more recent articles regarding risk factors and inflammation. There is a significant body of evidence that associates cardiovascular autonomic neuropathy (CAN) with most risk factors and with inflammation. It is known that CAN is associated with increased morbidity and mortality risk. The associations with traditional and nontraditional, as well as modifiable and nonmodifiable, risk factors, including inflammation, have historically made CAN a difficult diagnosis, especially since the perception has been that CAN is not treatable. This chapter concludes by explaining that this perception is not correct and discusses, generally, possible treatment modalities. Within the community of P&S monitoring, CAN has become an important diagnosis to document as early as possible to help avoid increased morbidity and mortality risk that leads to greater medication loads and hospitalization rates, causing greater healthcare costs.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Tsuji H, Venditti Jr FJ, Manders ES, Evans JC, Larson MG, Feldman CL, Levy D. Reduced heart rate variability and mortality risk in an elderly cohort. The Framingham Heart Study. Circulation. 1994;90(2):878–83.
DePace NL, Mears JP, Yayac M, Colombo J. Cardiac autonomic testing and diagnosing heart disease. “A clinical perspective.” Accepted Heart International. 2014.
DePace NL, Mears JP, Yayac M, Colombo J. Cardiac autonomic testing and treating heart disease. “A clinical perspective.” Accepted Heart International. 2014.
Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics—2008 update. Circulation. 2008;117(4):e25–146.
Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics—2010 update. Circulation. 2010;121(7):e46–215.
Writing Group Members, Roger VL, Go AS, Lloyd-Jones DM, et al. Executive summary: heart disease and stroke statistics—2012 update. Circulation. 2012;125(1):188–97.
U.S. Department of Health and Human Services (HHS). Prevention makes common “Cents”. Washington, DC: U.S. Department of Health and Human Services; 2003. p. 35.
Bangalore S, Steg G, Deedwania P, for the REACH Registry Investigators, et al. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308(13):1340–9.
Fau DT, Fau MG, Moore Jr F. Epidemiological approaches to heart disease: the Framingham study. Am J Public Health Nations Health. 1951;41(3):271–81.
Wilson PWF, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97(18):1837–47.
National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143–421.
Meigs JB, Larson MG, D’Agostino RB, et al. Coronary artery calcification in type 2 diabetes and insulin resistance. Diabetes Care. 2002;25(8):1313–9.
Karim R, Hodis HN, Detrano R, Liu CR, Liu CH, Mack WJ. Relation of Framingham risk score to subclinical atherosclerosis evaluated across three arterial sites. Am J Cardiol. 2008;102(7):825–30.
Kannel WB, Evans JC, Piper S, Murabito JM. Angina pectoris is a stronger indicator of diffuse vascular atherosclerosis than intermittent claudication: Framingham study. J Clin Epidemiol. 2008;61(9):951–7.
Oyama N, Gona P, Salton CJ, et al. Differential impact of age, sex, and hypertension on aortic atherosclerosis. Arterioscler Thromb Vasc Biol. 2008;28(1):155–9.
Junyent M, Zambón D, Gilabert R, Núñez I, Cofán M, Ros E. Carotid atherosclerosis and vascular age in the assessment of coronary heart disease risk beyond the Framingham Risk Score. Atherosclerosis. 2008;196(2):803–9.
Ridker PM, Paynter NP, Rifai N, Gaziano JM, Cook NR. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation. 2008;118(22):2243–51.
Kumar V, Abbas AK, Fausto N, Mitchell RS, editors. Robbins basic pathology. 8th ed. Philadelphia: Saunders Elsevier; 2007.
Ahrens EH. Drugs spotlight program: the management of hyperlipidemia: whether, rather than how. Ann Intern Med. 1976;85(1):87–93.
Chonchol M, Cook T, Kjekshus J, Pedersen TR, Lindenfeld J. Simvastatin for secondary prevention of all-cause mortality and major coronary events in patients with mild chronic renal insufficiency. Am J Kidney Dis. 2007;49(3):373–82.
Libby P. The forgotten majority: unfinished business in cardiovascular risk reduction. J Am Coll Cardiol. 2005;46(7):1225–8.
Pyörälä K, Ballantyne CM, Gumbiner B, et al. Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome. Diabetes Care. 2004;27(7):1735–40.
Crea F, Monaco C, Lanza GA, et al. Inflammatory predictors of mortality in the Scandinavian Simvastatin Survival Study. Clin Cardiol. 2002;25(10):461–6.
Robins S. Low high-density lipoprotein cholesterol and response to simvastatin therapy in scandinavian simvastatin survival study (4S). Circulation. 2002;106(2):e8.
Wang TJ, Stafford RS, Ausiello JC, Chaisson CE. Randomized clinical trials and recent patterns in the use of statins. Am Heart J. 2001;141(6):957–63.
Pedersen TR, Wilhelmsen L, Faergeman O, et al. Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering. Am J Cardiol. 2000;86(3):257–62.
Haffner SM, Alexander CM, Cook TJ, et al. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. Arch Intern Med. 1999;159(22):2661–7.
Pedersen TR. Coronary artery diseases: the Scandinavian Simvastatin Survival Study experience. Am J Cardiol. 1998;82(10B):53T–6.
Hsia J, MacFadyen JG, Monyak J, Ridker PM. Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin: the JUPITER trial (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin). J Am Coll Cardiol. 2011;57(16):1666–75.
DePace NL, Dowinsky SK. The heart repair manual: the Philadelphia formula program for preventing and reversing atherosclerosis. New York: W.W. Norton & Company; 1993.
Fau FE, Foy AF, Newman E. Goal-directed antihypertensive therapy: lower may not always be better. Cleve Clin J Med. 2011;78(2):123–33.
Gerstein HC, Miller ME, Genuth S, Ismail-Beigi F, Buse JB, Goff Jr DC, Probstfield JL, Cushman WC, Ginsberg HN, Bigger JT, Grimm Jr RH, Byington RP, Rosenberg YD, Friedewald WT on behalf of the ACCORD Study Group. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med. 2011;364(9):818–28.
Vinik A, Ziegler D. Diabetic cardiovascular autonomic neuropathy. Circulation. 2007;115:387–97.
Ewing DJ, Campbell IW, Clarke BF. Assessment of cardiovascular effects in diabetic autonomic neuropathy and prognostic implications. Ann Intern Med. 1980;92(2 Part 2):308–11.
Vinik AI, Maser RE, Nakave AA. Diabetic cardiovascular autonomic nerve dysfunction. US Endocr Dis. 2007;2:2–9.
Maser R, Mitchell B, Vinik AI, Freeman R. The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes, a meta analysis. Diabetes Care. 2003;26(6):1895–901.
Bullinga JR, Alharethi R, Schram MS, Bristow MR, Gilbert EM. Changes in heart rate variability are correlated to hemodynamic improvement with chronic CARVEDILOL therapy in heart failure. J Card Fail. 2005;11(9):693–9.
Copie X, Lamaison D, Salvador M, Sadoul N, DaCosta A, Faucher L, Legal F, Le Heuzey JY, VALID Investigators. Heart rate variability before ventricular arrhythmias in patients with coronary artery disease and an implantable cardioverter defibrillator. Ann Noninvasive Electrocardiol. 2003;8(3):179–84.
Alter P, Grimm W, Vollrath A, Czerny F, Maisch B. Heart rate variability in patients with cardiac hypertrophy–relation to left ventricular mass and etiology. Am Heart J. 2006;151(4):829–36.
Hayano J, Mukai S, Sakakibara M, Okada A, Takata K, Fujinami T. Effects of respiratory interval on vagal modulation of heart rate. Am J Physiol Heart Circ Physiol. 1994;267(36):H33–40.
Curtis BM, O’Keefe JH. Autonomic tone as a cardiovascular risk factor: the dangers of chronic fight or flight. Mayo Clin Proc. 2002;77:45–54.
Barakat HA, Mooney N, O’Brien K, et al. Coronary heart disease risk factors in morbidly obese women with normal glucose tolerance. Diabetes Care. 1993;16(1):144–9.
Ziegler D, Zentai CP, Perz S, Rathmann W, Haastert B, Doring A, Meisinger C. Prediction of mortality using measures of cardiac autonomic dysfunction in the diabetic and nondiabetic population: the MONICA/KORA Augsburg Cohort Study. Diabetes Care. 2008;31:556–61.
Bilchick KC, Fetics B, Djoukeng R, et al. Prognostic value of heart rate variability in chronic congestive heart failure (Veterans Affairs’ Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure). Am J Cardiol. 2002;90(1):24–8.
Batchvarov V, Hnatkova K, Ghuran A, Poloniecki J, Camm AJ, Malik M. Ventricular gradient as a risk factor in survivors of acute myocardial infarction. Pacing Clin Electrophysiol. 2003;26(1 Pt 2):373–6.
Ghuran A, Reid F, La Rovere MT, ATRAMI Investigators. Heart rate turbulence-based predictors of fatal and nonfatal cardiac arrest (the autonomic tone and reflexes after myocardial infarction substudy). Am J Cardiol. 2002;89(2):184–90.
Barthel P, Bauer A, Müller A, et al. Reflex and tonic autonomic markers for risk stratification in patients with type 2 diabetes surviving acute myocardial infarction. Diabetes Care. 2011;34(8):1833–7.
Liao D, Cai J, Rosamond WD, et al. Cardiac autonomic function and incident coronary heart disease: a population-based case-cohort study. Am J Epidemiol. 1997;145(8):696–706.
Gerstein HC, Mann JFE, Yi Q, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001;286(4):421–6.
Hermans MMH, Henry R, Dekker JM, et al. Estimated glomerular filtration rate and urinary albumin excretion are independently associated with greater arterial stiffness: the Hoorn Study. J Am Soc Nephrol. 2007;18(6):1942–52.
Hermans MMH, Henry RMA, Dekker JM, Nijpels G, Heine RJ, Stehouwer CDA. Albuminuria, but not estimated glomerular filtration rate, is associated with maladaptive arterial remodeling: the Hoorn Study. J Hypertens. 2008;26(4):791–7.
Fauci AS, Braunwald E, Kasper DL, et al. Harrison’s principles of internal medicine. 17th ed. New York: McGraw-Hill Professional; 2008.
Zheng ZJ, Croft JB, Giles WH, Mensah GA. Sudden cardiac death in the United States, 1989 to 1998. Circulation. 2001;104(18):2158–63.
Burke AP, Farb A, Malcom GT, Liang Y, Smialek J, Virmani R. Effect of risk factors on the mechanism of acute thrombosis and sudden coronary death in women. Circulation. 1998;97(21):2110–6.
Centers for Disease Control and Prevention (CDC). Decline in deaths from heart disease and stroke–United States, 1900–1999. MMWR Morb Mortal Wkly Rep. 1999;48(30):649–56.
Myerburg RJ. Scientific gaps in the prediction and prevention of sudden cardiac death. J Cardiovasc Electrophysiol. 2002;13(7):709–23.
Fox CS, Evans JC, Larson MG, Kannel WB, Levy D. Temporal trends in coronary heart disease mortality and sudden cardiac death from 1950 to 1999. Circulation. 2004;110(5):522–7.
Jouven X, Empana J, Schwartz PJ, Desnos M, Courbon D, Ducimetière P. Heart-rate profile during exercise as a predictor of sudden death. N Engl J Med. 2005;352(19):1951–8.
Cole CR, Blackstone EH, Ashkow FJP, Snader CE, Lauer MS. Heart-rate recovery immediately after exercise as a predictor of mortality. N Engl J Med. 1999;341:1351–7.
Vinik AI, Maser RE, Ziegler D. Neuropathy. The crystal ball for cardiovascular disease. Diabetes Care. 2010;33(7):1688–90.
Vinik AI, Maser RE, Ziegler D. Autonomic imbalance: prophet of doom or scope for hope? Diabet Med. 2011;28:643–51.
Vinik AI, Murray GL. Autonomic neuropathy is treatable. US Endocrinol. 2008;2:82–4.
Umetani K, Singer DH, McCraty R, Atkinson M. Twenty-four hour time domain heart rate variability and heart rate: relations to age and gender over nine decades. J Am Coll Cardiol. 1998;31(3):593–601.
Litchman JH, Bigger Jr JT, Blumenthal JA, et al. Depression and coronary heart disease recommendations for screening, referral, and treatment: A science advisory from the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care and Outcomes Research: Endorsed by the American Psychiatric Association. Circulation. 2008;118:1768–75.
Arora RR, Ghosh Dastidar S, Colombo J Autonomic balance is associated with decreased morbidity. American Autonomic Society, 17th International Symposium, Kauai. 29 Oct–1 Nov 2008.
Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes Care. 2003;26(5):1553–79.
Joint Editorial Statement by the American Diabetes Association; the National Heart, Lung, and Blood Institute; the Juvenile Diabetes Foundation International; the National Institute of Diabetes and Digestive and Kidney Diseases; and the American Heart Association. Diabetes mellitus: a major risk factor for cardiovascular disease. Circulation. 1999;100:1132–3.
Grundy SM, Benjamin IJ, Burke GL, Chait A. AHA Scientific Statement: diabetes and cardiovascular disease, a statement for healthcare professionals from the American Heart Association. Circulation. 1999;100:1134–46.
Low PA, Therapeutics and Technology Assessment Subcommittee. Assessment: clinical autonomic testing report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 1996;46:873–80.
Aring AM, Jones DE, Falko JM. Evaluation and prevention of diabetic neuropathy. Am Fam Physician. 2005;71:2123–30.
Leenen FHH. Brain mechanisms contributing to sympathetic hyperactivity and heart failure. Circ Res. 2007;101:221–3.
Sandroni P, Opfer-Gehrking TL, Singer W, Low PA. Pyridostigmine for treatment of neurogenic orthostatic hypotension: a follow up survey study. Clin Auton Res. 2005;15:51–3.
Arumanayagam M, Chan S, Tong S, Sanderson JE. Antioxidant properties of carvedilol and metoprolol in heart failure: a double-blind randomized controlled trial. J Cardiovasc Pharmacol. 2001;37:48–54.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Colombo, J., Arora, R., DePace, N.L., Vinik, A.I. (2015). Cardiovascular Autonomic Neuropathy: Risk Factor or Risk Indicator. In: Clinical Autonomic Dysfunction. Springer, Cham. https://doi.org/10.1007/978-3-319-07371-2_9
Download citation
DOI: https://doi.org/10.1007/978-3-319-07371-2_9
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-07370-5
Online ISBN: 978-3-319-07371-2
eBook Packages: MedicineMedicine (R0)